MBX Biosciences, Inc. (MBX)

MBX Biosciences Statistics

Total Valuation

MBX Biosciences has a market cap or net worth of $1.55 billion. The enterprise value is $1.15 billion.

Market Cap	1.55B
Enterprise Value	1.15B

Important Dates

The last earnings date was Thursday, November 6, 2025, before market open.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

MBX Biosciences has 44.90 million shares outstanding. The number of shares has increased by 1,225.35% in one year.

Current Share Class	44.90M
Shares Outstanding	44.90M
Shares Change (YoY)	+1,225.35%
Shares Change (QoQ)	+2.25%
Owned by Insiders (%)	2.85%
Owned by Institutions (%)	68.40%
Float	26.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.90
P/TBV Ratio	3.97
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 32.95, with a Debt / Equity ratio of 0.00.

Current Ratio	32.95
Quick Ratio	32.60
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -24.43% and return on invested capital (ROIC) is -17.22%.

Return on Equity (ROE)	-24.43%
Return on Assets (ROA)	-16.64%
Return on Invested Capital (ROIC)	-17.22%
Return on Capital Employed (ROCE)	-23.42%
Revenue Per Employee	n/a
Profits Per Employee	-$1.87M
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +64.47% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+64.47%
50-Day Moving Average	20.32
200-Day Moving Average	13.31
Relative Strength Index (RSI)	84.98
Average Volume (20 Days)	711,388

Short Selling Information

The latest short interest is 4.58 million, so 10.20% of the outstanding shares have been sold short.

Short Interest	4.58M
Short Previous Month	3.91M
Short % of Shares Out	10.20%
Short % of Float	17.48%
Short Ratio (days to cover)	4.61

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-90.87M
Pretax Income	-80.50M
Net Income	-80.50M
EBITDA	-90.62M
EBIT	-90.87M
Earnings Per Share (EPS)	-$2.39

Balance Sheet

The company has $391.67 million in cash and $623,000 in debt, giving a net cash position of $391.05 million or $8.71 per share.

Cash & Cash Equivalents	391.67M
Total Debt	623,000
Net Cash	391.05M
Net Cash Per Share	$8.71
Equity (Book Value)	387.54M
Book Value Per Share	8.67
Working Capital	385.44M

Cash Flow

In the last 12 months, operating cash flow was -$77.69 million and capital expenditures -$1.23 million, giving a free cash flow of -$78.91 million.

Operating Cash Flow	-77.69M
Capital Expenditures	-1.23M
Free Cash Flow	-78.91M
FCF Per Share	-$1.76

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

MBX Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,225.35%
Shareholder Yield	-1,225.35%
Earnings Yield	-5.23%
FCF Yield	-5.13%

Analyst Forecast

The average price target for MBX Biosciences is $56.17, which is 62.86% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$56.17
Price Target Difference	62.86%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-11.68%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2